Another innovative CD19-directed alloCAR T (PBCAR0191) was evaluated in a phase 1/2a trial for patients with B-cell malignancies (ie. B-NHL and B-ALL) (16). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.